Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

IPC

Displaying 1 to 10 of 58 Posts . Displaying 10 of Posts . Page of 6 . Go To Page: . Per Page: . . . View All Sort By: .

AbbVie Launches Let Me Be Clear to Empower People with Psoriasis to Speak Up and Seek Freedom from Their Disease

AbbVie, a research-based global biopharmaceutical company, today announced the launch of Let Me Be Clear, an empowerment platform for people living with psoriasis. The initiative, which launches on World Psoriasis Day, invites people living with psoriasis to share their story, discuss what freedom from psoriasis would mean to them and access tools to have clear and informed conversations with their physicians.

Read More

Announcing IPC's Newest Corporate Partner: Ortho Dermatologics

Announcing IPC's Newest Corporate Partner: Ortho Dermatologics IPC would like to thank our newest Corporate Partner, Ortho Dermatologics. Ortho Dermatologics is one of the largest prescription dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and corticosteroid responsive...

Read More

Get Connected: World Psoriasis Day 2019

Get Connected: World Psoriasis Day 2019 The International Psoriasis Council (IPC) strives to deepen the understanding of psoriasis and its management by leading advancements in care by facilitating cutting-edge research, convening partners to collaborate and advocate for improved treatment, and growing capacity for psoriasis management by sharing our knowledge. IPC dreams of a world free of psoriasis. We believe that psoriasis patients, no matter where they live in the world, no matter...

Read More

In Memory of Gladys León Dorantes

   Gladys Leon Dorantes with her IPC colleagues participating in a meeting of the IPC Latin America Working Group this past May at RADLA in Buenos Aires, Argentina Argentina Gladys León Dorantes  was a well-known dermatologist and psoriasis expert working in Mexico City, Mexico since 1994. She was a founding member and long-serving president of the Asociación...

Read More

Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council

Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, due to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be mis-categorized, which can lead to under-treatment of psoriasis.

Read More

Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis

Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).

Read More

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

Read More

Updated Disease Classification System Adopted by the World Health Organization

On 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022.

Read More

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below.

Read More

Meta-Analysis Shows Patients With Psoriasis at Significantly Elevated Risk for Cancer

In a study presented at the British Association of Dermatologists’ 99th Annual Meeting in Liverpool, United Kingdom, July 2-4, 2019, researchers from the University of Manchester and the Salford Royal National Health Service Foundation Trust reported on an effort to assess evidence on the risk of cancer in patients with psoriasis.

Read More
UPCOMING EVENT

Challenging cases in psoriasis: A focus on systemics, TB and pustular psoriasis

Wednesday, February 26, 2020
2:00 pm - 3:30 pm
Bangkok, Thailand
Register Now

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

We use cookies on this website to enhance your experience. By continuing with this website, you consent to our use of cookies. Learn more.
OK